Identification of a New Intronic BMPR2-Mutation and Early Diagnosis of Heritable Pulmonary Arterial Hypertension in a Large Family with Mean Clinical Follow-Up of 12 Years
Background Mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene can lead to hereditary pulmonary arterial hypertension (HPAH) and are detected in more than 80% of cases with familial aggregation of the disease. Factors determining disease penetrance are largely unknown. Methods A mean clinical follow-up of 12 years was accomplished in 46 family members including echocardiography, stress-Dopplerechocardiography and genetic analysis of TGF-β pathway genes. Right heart catheterization and RNA-analysis was performed in members with pathological findings. Results Manifest HPAH was diagnosed in 8 members, 4 were already deceased, two died during the follow-up, two are still alive. Normal pulmonary artery systolic pressure at rest but hypertensive response to exercise has been identified in 19 family members. Analysis of BMPR2 transcripts revealed aberrant splicing due to an insertion of an intronic Alu element adjacent to exon 6. All HPAH patients and 12 further asymptomatic family members carried this insertion. During follow-up two family members carrying hypertensive response and the Alu insertion developed manifest HPAH. Conclusion This is the first report of an intronic BMPR2 mutation due to an Alu element insertion causing HPAH in a large family which has been confirmed on RNA-level. Only those members that carried both hypertensive response and the mutation developed manifest HPAH during follow-up. Our findings highlight the importance of including further methods such as RNA analysis into the molecular genetic diagnostic of PAH patients. They suggest that at least in some families hypertensive response may be an additional risk factor for disease manifestation and penetrance.
References
[1]
Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493–537. doi: 10.1093/eurheartj/ehr046
[2]
Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, et al. (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol 168: 871–80. doi: 10.1016/j.ijcard.2012.10.026
[3]
Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, et al. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81–4.
[4]
Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737–44. doi: 10.1086/303059
[5]
Machado RD, Aldred MA, James V, Harrison RE, Patel B, et al. (2006) Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 27: 121–32. doi: 10.1002/humu.20285
[6]
Trembath RC (2001) Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity. J Heart Lung Transplant 20: 175. doi: 10.1016/s1053-2498(00)00352-1
[7]
Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, et al. (2004) Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59: 446–8. doi: 10.1136/thx.2003.11890
[8]
Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R (2009) A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 46: 331–7. doi: 10.1136/jmg.2008.062703
[9]
Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, et al. (2009) Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 30: S32–42. doi: 10.1016/j.jacc.2009.04.015
[10]
Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, et al. (2011) Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 12: 99. doi: 10.1186/1465-9921-12-99
[11]
Austin ED, Loyd JE (2013) Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 34: 568–80. doi: 10.1055/s-0033-1355443
[12]
Loyd JE, Primm RK, Newman JH (1984) Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 129: 194–7.
[13]
Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA 3rd, et al. (1995) Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 152: 93–7. doi: 10.1164/ajrccm.152.1.7599869
[14]
Grünig E, Barner A, Bell M, Claussen M, Dandel M, et al. (2011) Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. Int J Cardiol 154 Suppl 1S3–12. doi: 10.1016/s0167-5273(11)70488-0
[15]
Olschewski H (2006) Current recommendations for the diagnosis and treatment of pulmonary hypertension. Dtsch Med Wochenschr. 131: S334–7. doi: 10.1055/s-2006-933708
[16]
Trip P, Vonk-Noordegraaf A, Bogaard HJ (2012) Cardiopulmonary exercise testing reveals onset of disease and response to treatment in a case of heritable pulmonary arterial hypertension. Pulm Circ 387–389.
[17]
Grunig E, Janssen B, Mereles D, Barth U, Borst MM, et al. (2000) Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102: 1145–50. doi: 10.1161/01.cir.102.10.1145
[18]
Janssen B, Rindermann M, Barth U, Miltenberger-Miltenyi G, Mereles D, et al. (2002) Linkage analysis in a large family with primary pulmonary hypertension: genetic heterogeneity and a second primary pulmonary hypertension locus on 2q31–32. Chest 121: 54S–56S. doi: 10.1378/chest.121.3_suppl.54s
[19]
Grunig E, Weissmann S, Ehlken N, Fijalkowska A, Fischer C, et al. (2009) Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 119: 1747–57. doi: 10.1161/circulationaha.108.800938
[20]
Ommen SR, Nishimura RA, Hurrell DG, Klarich KW (2000) Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc. 75: 24–9. doi: 10.4065/75.1.24
[21]
Bird AG, McLachlan SM, Britton S (1981) Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 289: 300–1. doi: 10.1038/289300a0
[22]
Oh HM, Oh JM, Choi SC, Kim SW, Han WC, et al. (2003) An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes. Cell Prolif 36: 191–7. doi: 10.1046/j.1365-2184.2003.00276.x
[23]
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–9. doi: 10.1016/0003-2697(87)90021-2
[24]
Rindermann M, Grunig E, von Hippel A, Koehler R, Miltenberger-Miltenyi G, et al. (2003) Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31. J Am Coll Cardiol 41: 2237–44. doi: 10.1016/s0735-1097(03)00491-1
[25]
Ferlini A, Muntoni F (1998) The 5′ region of intron 11 of the dystrophin gene contains target sequences for mobile elements and three overlapping ORFs. Biochem Biophys Res Commun 242: 401–6. doi: 10.1006/bbrc.1997.7976
[26]
Ganguly A, Dunbar T, Chen P, Godmilow L, Ganguly T (2003) Exon skipping caused by an intronic insertion of a young Alu Yb9 element leads to severe hemophilia A. Hum Genet 113: 348–52. doi: 10.1007/s00439-003-0986-5
[27]
Ricci V, Regis S, Di Duca M, Filocamo M (2003) An Alu-mediated rearrangement as cause of exon skipping in Hunter disease. Hum Genet 112: 419–25.
[28]
Wallace MR, Andersen LB, Saulino AM, Gregory PE, Glover TW, Collins FS (1991) A de novo Alu insertion results in neurofibromatosis type 1. Nature 353: 864–6. doi: 10.1038/353864a0
[29]
Kaer K, Speek M (2013) Retroelements in human disease. Gene 518: 231–41. doi: 10.1016/j.gene.2013.01.008
[30]
Lev-Maor G, Sorek R, Shomron N, Ast G (2003) The birth of an alternatively spliced exon: 3′ splice-site selection in Alu exons. Science 300: 1288–91. doi: 10.1126/science.1082588
[31]
Deininger PL, Batzer MA (1999) Alu repeats and human disease. Mol Genet Metab 67: 183–93. doi: 10.1006/mgme.1999.2864
[32]
Li X, Scaringe WA, Hill KA, Roberts S, Mengos A, et al. (2001) Frequency of recent retrotransposition events in the human factor IX gene. Hum Mutat 17: 511–9. doi: 10.1002/humu.1134
[33]
Xing J, Zhang Y, Han K, Salem AH, Sen SK, et al. (2009) Mobile elements create structural variation: analysis of a complete human genome. Genome Res 19: 1516–26. doi: 10.1101/gr.091827.109
[34]
Batzer MA, Deininger PL (2002) Alu repeats and human genomic diversity. Nat Rev Genet 3: 370–9. doi: 10.1038/nrg798
[35]
Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, et al. (2013) Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol 110: 586–93. doi: 10.1016/j.amjcard.2012.12.032
[36]
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, et al. (2010) Predicting Survival in Pulmonary Arterial Hypertension - Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122: 164–172. doi: 10.1161/circulationaha.109.898122
